A imunização deve ser entendida como um regulador no processo saúde-doençae é uma das formas mais seguras e eficazesde prevenir enfermidades edereduzir a propagação de doenças existentes. Apesar disso, omovimento antivacinação alcançou uma ascendênciamundial,fator que pode provocar conse...quências desastrosas e moldar o percurso da doença e do cuidadona população. Dessa forma, o objetivo desta revisão literária é evidenciaros dados de cobertura vacinale discutir as razões pelas quais o movimento antivacina ocorreem um contexto de globalização e mídias sociais,bem como os impactos provocados na saúde brasileira.
more
2nd edition, July 2021. This WHO and HRP guideline is designed to help countries make faster progress, more equitably, on the screening and treatment of cervical cancer. It includes some important shifts in WHO’s recommended approaches to cervical screening, and includes a total of 23 recommendati...ons and 7 good practice statements.
Among the 23 recommendations, 6 are identical for both the general population of women and for women living with HIV and 12 are different and specific for each population.
Among the 7 good practice statements, 3 are identical for both the general population of women and for women living with HIV and 2 are different and specific for each population
more
La presente publicación describe la literatura científica revisada sobre las intervenciones farmacológicas para el tratamiento de la enfermedad por el coronavirus 2019. El Ministerio de Salud solicitó la revisión de la evidencia disponible para nueve intervenciones terapéuticas frente a COVID-...19. Este listado contempla 03 intervenciones que no fueron consideradas en la Revisión Rápida de Intervenciones farmacológicas para el tratamiento de la enfermedad por el coronavirus 2019 . Serie Revisión Rápida N° 02-2020, correspondiendo a Ivermectina, Tocilizumab y pulsos de corticoides. En vista del rol potencial de cada intervención en el tratamiento de COVID-19, se plantearon dos respuestas PICO a fin de revisar la evidencia disponible respecto a siete potenciales opciones para tratamiento específico y dos fármacos que se han señalado como terapia adyuvante para frenar la respuesta inflamatoria presentada en COVID-19.
Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19.
more
La presente publicación describe la evidencia científica disponible sobre la utilidad del uso complementario de pruebas moleculares y de detección de anticuerpos para mejorar el diagnóstico de sospechosos de COVID-19. La utilización complementaria de ambas pruebas podría mejorar la identificac...ión correcta de pacientes con COVID-19, incluyendo a los pacientes asintomáticos o con enfermedad leve, contribuyendo a disminuir su propagación.
Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19
more
La presente publicación describe la evidencia científica disponible sobre la precisión diagnóstica de las pruebas rápidas de detección de antígenos para SARS-COV-2. El conocimiento de las pruebas diagnósticas para el coronavirus del síndrome respiratorio agudo grave 2 (SARS-COV-2) sigue evo...lucionando, y una comprensión clara de la naturaleza de las pruebas y la interpretación de sus hallazgos es importante. Este punto de vista describe cómo interpretar 2 tipos de pruebas diagnósticas comúnmente en uso para las infecciones SARS-COV-2: reacción en cadena de polimerasa con transcriptasa reversa (RT-PCR) y ensayo por inmunoabsorción ligado a enzimas IgM e IgG (ELISA)— y cómo los resultados pueden variar con el tiempo.
Esta publicación pertenece al compendio Publicaciones Minsa sobre COVID-19
more
Interim guidance, 26 October 2021
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.
SAGE said moderately and severely immunocompromised persons should be offered an addition...al dose of all WHO approved vaccines “since these individuals are less likely to respond adequately to vaccination following a standard primary vaccine series and are at high risk of severe COVID-19 disease.”
People aged 60 and older who received the Sinovac and Sinopharm vaccines should get a third dose too, the experts added, though use of other vaccines may also be considered depending on supply and access.
“When implementing this recommendation, countries should initially aim at maximizing 2-dose coverage in that population, and thereafter administer the third dose, starting in the oldest age groups”, they said.
SAGE has also reviewed a vaccine developed by Indian company Bharat Biotech and will issue a policy recommendation after WHO greenlights it for emergency use.
more
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
A study conducted by the World Health Organisation Regional Office for Africa. The COVID-19 pandemic has had a significant impact on older persons both globally and in the African region. Although overall the region’s population is younger relative to many other world regions, the WHO AFRO region ...has a population just over 62 million older people and is ageing rapidly, with the number of older people expected to triple in the next three decades (Aboderin et al., 2020).
more
Following review of evidence and advice from the Technical Advisory Group (TAG) on Tuberculosis (TB) Diagnostics and Laboratory Strengthening, the World Health Organization (WHO) announces that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beij...ing Wantai’s TB-IGRA and Qiagen QuantiFERON-TB Gold Plus products. This expands the range of tests available to detect TB infection. Full details are provided in this WHO policy statement.
more
List of essential medicines for the management of patients admitted in intensive care units with a suspected or confirmed diagnosis of COVID 19. Third version, 1 February 2022
Global Health Science and Practice February 2022, https://doi.org/10.9745/GHSP-D-21-00237
Key Findings: Exposure to vaccination information from faith leaders and health facilities was associated with increased likelihood of vaccination uptake. The significant association between exposure to a... greater number of immunization information sources and increased likelihood of vaccination uptake reinforces the need for multiple sources to provide consistent and accurate immunization information to facilitate positive vaccination behavior.
Key Implications: Social and behavior change communication interventions may optimize the promotion of immunization services through multiple information sources such as health facilities and community-based assets including faith leaders and lay community health workers. Religion and faith play an important role in how people understand health and make health decisions. In Sierra Leone and other similar settings, interventions to improve uptake of immunization services may be enhanced by proactively engaging faith leaders.
more
This guideline aims to improve the quality of essential, routine postnatal care for women and newborns with the ultimate goal of improving maternal and newborn health and well-being. It recognizes a “positive postnatal experience” as a significant end point for all women giving birth and their n...ewborns, laying the platform for improved short- and long-term health and well-being. A positive postnatal experience is defined as one in which women, newborns, partners, parents, caregivers and families receive information, reassurance and support in a consistent manner from motivated health workers; where a resourced and flexible health system recognizes the needs of women and babies, and respects their cultural context.
This is a consolidated guideline of new and existing recommendations on routine postnatal care for women and newborns receiving facility- or community-based postnatal care in any resource setting.
more
Emergencias 2021: 33: 42-58
2nd edition. These guidelines include several notable changes from the first edition. For cutaneous leishmaniasis, ketoconazole has been removed from the list of treatment options; the number of Leishmania species for which there is strong evidence for the efficacy of miltefosine has increased from ...two to four; and the recommendation for intralesional antimonials is now strong. For mucosal leishmaniasis there is now a strong recommendation for use of pentavalent antimonials with or without oral pentoxifylline. For visceral leishmaniasis, the strong recommendations for use of pentavalent antimonials and amphotericin B deoxycholate are now conditional.
more
El Programa Nacional de Chagas ha definido la utilización de dos medicamentos para el tratamiento de la Enfermedad de Chagas Crónico Reciente Infantil (en niños de 9 meses a menor de 15 años); el benznidazol (BNZ) que será utilizado como medicamento de primera elección en todos los casos con d...iagnóstico serológico positivo confirmado y el nifurtimox (NFT) que será utilizado como segunda alternativa en aquellos casos que hubieran presentado reacciones adversas graves al benznidazol, e indiquen un cambio de conducta.
more
Manual de Normas para el Diagnóstico y Tratamiento de Chagas Congénito
Este manual pretende estandarizar la práctica del SFT para que el QF pueda trabajar
con los usuarios de forma consistente y estandarizada a nivel nacional.